AUT00201 / Autifony Therap - LARVOL DELTA

AUT022201: Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Autifony Therapeutics Limited | Recruiting ➔ Completed | N=10 ➔ 6

Enrollment change • Trial completion • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

AUT022201: Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Autifony Therapeutics Limited | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

A Potent and Novel Potassium Channel Positive Modulator AUT00201 Attenuates Cellular Dysfunction, Ataxia, and Seizure Susceptibility in a Mouse Model of Progressive Myoclonus Epilepsy Type 7 (AES 2023) - "Previously, we demonstrated that the complex features of EPM7 correlate with the dysfunction of Kv3.1-expressing neurons in distributed brain regions in a novel mouse model of EPM7, Kcnc1-p.Arg320His/+ (H/+) mice, and investigated the therapeutic potential of a Kv3 channel positive modulator, AUT00206. Kcnc1-p.Arg320H/+ mice exhibit progressive ataxia and enhanced seizure susceptibility, and hence reproduce key disease features of, and represent a model for, the study of EPM7. Impaired excitability of Kv3.1-expressing neurons in vitro and indices of cerebellar dysfunction and seizure susceptibility in vivo could be ameliorated with the potent Kv3-channel modulator AUT00201, which may demonstrate therapeutic potential for the treatment of human patients with EPM7."

Preclinical • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

AUT022201: Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Autifony Therapeutics Limited

New P1 trial • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

Safety, Blood Levels and Effects of AUT00201 (clinicaltrials.gov) - P1; N=80; Completed; Sponsor: Autifony Therapeutics Limited; Recruiting ➔ Completed; Trial completion date: Aug 2020 ➔ Dec 2020; Trial primary completion date: Aug 2020 ➔ Dec 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date